Actinogen Medical Limited (AU:ACW) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical has received a $9 million R&D tax incentive rebate from the Australian Tax Office, providing crucial funding to advance its Alzheimer’s clinical trials. This financial boost supports the company’s efforts to develop Xanamem, a promising treatment for neurological disorders linked to brain cortisol levels. Investors may find this development encouraging as it extends Actinogen’s cash runway until mid-2026, ensuring continued progress in their innovative therapies.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.